Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

Article  PubMed  Google Scholar 

Zhang, T. et al. Changing trends of disease burden of gastric cancer in China from 1990 to 2019 and its predictions: findings from Global Burden of Disease Study. Chin. J. Cancer Res. 33, 11–26 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ajani, J. A. et al. Gastric Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 20, 167–192 (2022).

Article  CAS  Google Scholar 

Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shitara, K. et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603, 942–948 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu, J. et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Ann. Oncol. 32, S1331 (2021).

Article  Google Scholar 

Zhang, Z. et al. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: current evidence and future perspectives. Chin. J. Cancer Res. 32, 287–302 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlößer, H. A. et al. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology 5, e1100789 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275–4280 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Selby, M. et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J. Clin. Oncol. 31, 3061 (2013).

Article  Google Scholar 

Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Antonia, S. J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17, 883–895 (2016).

Article  CAS  PubMed  Google Scholar 

Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).

Article  CAS  PubMed  Google Scholar 

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690–714 (2015).

Article  CAS  PubMed  Google Scholar 

Lynch, T. J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046–2054 (2012).

Article  CAS  PubMed  Google Scholar 

Reck, M. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 24, 75–83 (2013).

Article  CAS  PubMed  Google Scholar 

Pang, X. et al. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. mAbs 15, 2180794 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Keam, S. J. Cadonilimab: first approval. Drugs 82, 1333–1339 (2022).

Article  CAS  PubMed  Google Scholar 

Lei, M. et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab ± ipilimumab in gastric cancer/gastroesophageal junction cancer. Clin. Cancer Res. 27, 3926–3935 (2021).

Article  CAS  PubMed  Google Scholar 

Hagi, T. et al. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br. J. Cancer 123, 965–972 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fassan, M. et al. PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Arch. 477, 151–156 (2020).

Article  CAS  PubMed  Google Scholar 

Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181–1195 (2023).

Article  CAS  PubMed  Google Scholar 

Liu, T. et al. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. Int. J. Cancer 152, 749–760 (2023).

Article  CAS  PubMed  Google Scholar 

Shah, M. A. et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 3, 620–627 (2017).

Article  PubMed  Google Scholar 

Kang, Y.-K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017).

Article  CAS  PubMed  Google Scholar 

Boku, N. et al. LBA7_PR nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Ann. Oncol. 31, S1192 (2020).

Article  Google Scholar 

Al-Batran, S.-E. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 26, 1435–1442 (2008).

Article  CAS  PubMed  Google Scholar 

Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008).

Article  CAS  PubMed  Google Scholar 

Lorenzen, S. et al. FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: results from the randomized phase II Moonlight trial of the AIO. Ann. Oncol. 33, S1099 (2022).

Article  Google Scholar 

Lorenzen, S. et al. FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: a randomized phase 2 trial of the AIO. J. Clin. Oncol. 40, 4043 (2022).

Article  Google Scholar 

Ahn, M-J. et al. LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): a phase Ib/II trial. Ann. Oncol. 33, S1432 (2022).

Article  Google Scholar 

Hellmann, M. D. et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 18, 31–41 (2017).

Article  CAS  PubMed  Google Scholar 

Gao, X. et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial. Lancet Oncol. 24, 1134–1146 (2023).

Article  CAS  PubMed  Google Scholar 

Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).

Article  CAS  PubMed  Google Scholar 

Common Terminology Criteria for Adverse Events v.5.0 (National Cancer Institute, 2018); https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf